Eos Advisory

An Investment Committee comprising Managing Partner Andrew McNeill and Partners Chris Brinsmead, Rick Clark, and Ana Stewart, supported by Director of Portfolio Anne Muir and Investment Executive Calum Keddie, oversees investment decisions. The Angel Syndicate operates on a member-vote model where Eos arranges opportunities but individuals make their own choices. The Innovation Fund is fully managed by Eos on a discretionary basis.

Eos is rooted in the Scottish university and research ecosystem and leans on its team's scientific networks — several members are scientists, government advisors, or former founders — to identify IP-rich early-stage opportunities. The firm's St Andrews location and institutional ties give it proximity to deal flow that rarely reaches London-centric venture funds, and follow-on rounds are often grown out of the existing portfolio rather than the open market.

Eos operates a hybrid structure. It runs a traditional Angel Syndicate that accounts for about 13% of annual investments, a managed Innovation Fund closing annually with a pooled discretionary pool, and a Venture Partners vehicle for ad-hoc growth and Series A+ rounds. Minimum commitments range from £5,000 in the syndicate to £1 million-plus for venture partner deals, making it a multi-track platform rather than a pure VC or pure angel network.

The portfolio is split between quality of life — diagnostics, prevention, and treatment — and environmental sustainability, which includes food and water security, pollution, clean energy, and sustainable infrastructure. Known positions span disease diagnostics (Dxcover), sustainable materials (Naturbeads), agri-tech (Penhros Bio), and gene editing (Laverock Therapeutics).

Yes. Eos works with family offices, individuals, companies, and institutional investors on a long-term partnership basis. The Innovation Fund and Venture Partners vehicles are designed for external capital, while the Angel Syndicate originated as the firm's founding pillar and remains open to qualified individual investors seeking UK S/EIS tax relief where applicable.

Eos has deep roots in Scotland and invests primarily in UK science and technology companies at seed and growth stages. The firm maintains a global perspective — drawing investors from beyond the UK — but portfolio companies are overwhelmingly sourced from Scottish and wider UK research ecosystems. It operates from St Andrews and Edinburgh.

Eos offers S/EIS tax relief for relevant investors where available, particularly through its Angel Syndicate and early-stage Innovation Fund investments. The firm frames this as part of its remit to channel patient, risk-tolerant capital into knowledge-intensive companies, noting explicitly that these are high-risk investments where capital may be lost and liquidity is limited.